Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.1 , No. 1, Publication Date: Jul. 7, 2014, Page: 1-6
 and P53 in Endometrial Carcinoma and Correlated with of Histological Type, Grade and Stage&description=Objective. The differences in immunohistochemical expression of estrogen receptors (ER) and p53 in endometrial carcinoma and correlated with of histological type, grade and stage are crucial in the planning of further monitoring and treatment of patients. Materials and methods. This paper deals with data of the patients treated for endometrial carcinoma in Public Hospitals in Travnik, gynecological department in the period from 01.01.2007. to 01.01.2013th the sample consisted of 97 women with endometrial carcinoma, with ages ranging from 42 to 90 years (mean of 64 years). 72 cases (74.2%) were of endometrioid and 25 (25.8%) nonendometrioid carcinoma. Results. The 72 endometrioid carcinoma cases were final disease stage as follows: stage I = 29/72 (40%) and stages II, III et IV = 43/72 (60%). Markers and histological types: p53 expression was found in 10 patients (13.8%) of the endometrioid and 17 patients (68%) of the nonendometrioid endometrial carcinoma. The estrogen receptors were more frequent in the endometrioid type 44 patients (61%) with regard to 7 patients of the nonendometrioid type endometrial carcinoma. Markers and histological grade: In the 72 cases of endometrioid carcinoma, those with grade I expressed estrogen (22 out of 36 cases = 61.1%) more frequently than those with grades II and III. p53 was expressed in only 3.8% of endometrioid carcinomas. Conclusion. The different immunohistochemical profiles of endometrioid and nonendometrioid carcinomas confirm different molecular pathways in their development. The correlation of immunohistochemical findings with histological grade and clinical stage could help in predicting biologic behavior and planning treatment in patients who are diagnosed as having these tumors.&picture=http://www.aascit.org/aascit/decorators/img/journal/903.jpg)
| [1] | Sinisa Maksimovic , Depertment Oncological Surgery, Public hospital "St Vracevi", Bijeljina, Bosnia and Herzegovina. |
| [2] | Amer Suskic , Department of Gynecology, Public hospital Travnik, Travnik, Bosnia and Herzegovina. |
| [3] | Sanela Halilovic Suskic , Department of Gynecology, Public hospital Travnik, Travnik, Bosnia and Herzegovina. |
| [4] | Branislava Jakovljevic , Depertment Medical oncology, Health care institution "S- Tetik” Banja Luka, Bosnia and Herezegovina. |
| [5] | Dejan Opric , Depertment Pathology, Medical Faculty University of Belgrade, Belgrade, Serbia. |
| [6] | Dusan Mileusnic , Depertment Radiology, International Medical Centers Banja Luka, Bosnia and Herezegovina. |
Objective. The differences in immunohistochemical expression of estrogen receptors (ER) and p53 in endometrial carcinoma and correlated with of histological type, grade and stage are crucial in the planning of further monitoring and treatment of patients. Materials and methods. This paper deals with data of the patients treated for endometrial carcinoma in Public Hospitals in Travnik, gynecological department in the period from 01.01.2007. to 01.01.2013th the sample consisted of 97 women with endometrial carcinoma, with ages ranging from 42 to 90 years (mean of 64 years). 72 cases (74.2%) were of endometrioid and 25 (25.8%) nonendometrioid carcinoma. Results. The 72 endometrioid carcinoma cases were final disease stage as follows: stage I = 29/72 (40%) and stages II, III et IV = 43/72 (60%). Markers and histological types: p53 expression was found in 10 patients (13.8%) of the endometrioid and 17 patients (68%) of the nonendometrioid endometrial carcinoma. The estrogen receptors were more frequent in the endometrioid type 44 patients (61%) with regard to 7 patients of the nonendometrioid type endometrial carcinoma. Markers and histological grade: In the 72 cases of endometrioid carcinoma, those with grade I expressed estrogen (22 out of 36 cases = 61.1%) more frequently than those with grades II and III. p53 was expressed in only 3.8% of endometrioid carcinomas. Conclusion. The different immunohistochemical profiles of endometrioid and nonendometrioid carcinomas confirm different molecular pathways in their development. The correlation of immunohistochemical findings with histological grade and clinical stage could help in predicting biologic behavior and planning treatment in patients who are diagnosed as having these tumors.
Keywords
Endometrial Adenocarcinoma, Estrogen Receptors, p53, Immunohistochemistry
Reference
| [01] | Silverberg SG, Kurman RJ, Nogales F, Mutter G, Kubik-Huch RA, Tavassoli FA. Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press;2003.p.221-32. |
| [02] | Ronnett BM, Zaino RJ, Hedric Ellenson L, Kurman RJ. Endometri- al carcinoma. In: Kurman RJ, editor. Blauestein’s Pathology of the Female Genital Tract. 5th edition. New York: Springer-Verlag;2002.p.501-59. |
| [03] | Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res. 2005;322:53-61. |
| [04] | Sherwin R, Catalano R, Sharkey A. Large-scale gene expression studies of the endometrium: what have we learnt? Reproduction.2006;132:1-10. |
| [05] | Shiozawa T, Konishi I. Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis and treatment. The International Journal of Clinical Oncology.2006;11:13-21 |
| [06] | Sankaranarayanan R, Ferley J. Worlwide burden of gynecological cancer: the size of problem. Best Pract Res Clin Obstet Gynecol.2006;20:207-25 |
| [07] | Pearce ST, Jordan VC. The biological role of estrogen receptors α and β in cancer. Critical Reviews in Oncology/Hematology.2004;50:3-22 |
| [08] | Gehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer.2009;86(10):2083-89. |
| [09] | Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol.2008;13(4):379-88. |
| [10] | Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol.2004;93(1):34-40. |
| [11] | Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Research.2005;322:53-61 |
| [12] | Bozdogan O, Atasoy P, Erekul S, Bozdogan N, Bayram M. Apoptosis- related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol.2008;21:375-82. |
| [13] | Silverberg SG, Ioffe OB. Pathology of cervical cancer. Cancer Journal.2008;9(5):335-47. |
| [14] | Uharcek P. Prognostic factors in endometrial carcinoma. Journal of Obstetrics and Gynaecology Research.2008;34(5):776-83. |
| [15] | Engelsen IB, Akslen LA and Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS.2009;117(10):693-707. |
| [16] | Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. Journal of Steroid Biochemistry and Molecular Biology.2008:108(3-5):221-9. |
| [17] | Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression, Clinical Cancer Research.2005;11(17):6133-8. |
| [18] | Salvesen HB, Kumar R, Stefansson I, Angelini S, MacDonald N, Smeds J, et al. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer.2005;115(6):930-34. |
| [19] | Kawaguchi M, Yanokura M, Banno K, Kobayashi Y, Kuwabara Y, Kobayashi M, et al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. International Journal of Oncology.2009;34(6):1541-7. |
| [20] | Mizumoto Y, Kyo S, Mori N, Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Science.2007;(98):652-8. |
| [21] | Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu WSun et al, Her- 2/neu overexpression and amplification in uterine papillary serous carcinoma. Journal of Clinical Oncology.2004;22(15):3126-32. |
| [22] | Yuan TL. Cantley LC, PI3K pathway alterations in cancer: variations on a theme. Oncogene.2008;27(41):5497-510. |
| [23] | Shoji K, Oda K, Nakagawa S, S Hosokawa, G Nagae, Y Uehara et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. British Journal of Cancer.2009;101(1):145-8. |
| [24] | Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M, Somatic mutations are present in all members of the AKT family in endometrial carcinoma. British Journal of Cancer.2009;101(7):1218-9. |
| [25] | Byron SA, Gartside MG, Wellens CL, et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Research.2008;68(17):6902-07. |
| [26] | Byron SA, Pollock PM, FGFR2 as amolecular target in endometrial cancer. Future Oncology.2009;5(1):27-32. |
| [27] | Soufla G, Sifakis S, Spandidos DA, FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. Cancer Letters.2008;259(2):146-55. |
| [28] | Boruban MC, Altundag K, Kilic GS, Blankstein J, From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. European Journal of Cancer Prevention.2008;17(2):133-8. |
| [29] | Bansal N,Yendluri V, Wenham RM, The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.Cancer Control.2009;16(1):8-13. |
